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Background and aims Familial hypercholesterolemia (FH) is at very high
risk of early myocardial infarction (MI). The prevalence of FH, which is esti-
mated to be at least 1:500 in the general population, remains unclear in
patients with acute MI. From databases of 2 French regional and nationwide
registries of acute MI (RICO and FAST-MI, respectively), we aimed to deter-
mine FH prevalence by developing a specific algorithm.
Methods and results Consecutive patients with AMI ≤48 hours of onset
included 1) in FAST-MI: during a one-month period in 213 institutions at the
end of 2005 and 2) in RICO: from January 2001 December 2013 (≈13y), were
considered in the 2 databases. The algorithm was adapted from Dutch lipid
clinic network criteria and was build upon 4 variables (i.e. LDL level and pre-
vious use of lipid lowering medications, premature and family history) to
identify FH probability. The LDL level was adjusted on each type of lipid
lowering medications and the probability of FH was defined taking into
account missing data rate. Among the 7484 patients included in the RICO reg-
istry, 29.1% had premature vascular disease, 29.7% had familial history,
19.9% were under lipid lowering medications and 9.7% had LDL ≥5mmol/L.
FH prevalence was calculated as unlikely (72.6%), possible (24.6%) and prob-
able /definite (2.8%).
Conclusion Our 4-variables algorithm is relevant to determine FH proba-
bility in databases from MI registries. In this large population reflecting rou-
tine clinical practice in acute MI, a high prevalence of FH was found,
suggesting the opportunity for prevention strategies.
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Objectives To describe the characteristics and treatments of patients
having a myocardial infarction (MI) and estimate the incidence of cardio-
vascular events following the index MI, in the French Health Insurance
database.
Method A cohort of patients who had a MI in France between 2007 and
2011 was extracted from a claim database: the Echantillon Généraliste de
Bénéficiaires (a 1% representative sample of subjects covered by the gen-
eral health insurance (?600,000 patients). The incidence of cardiovascular
events following the index MI was estimated using the Kaplan Meier
method. 
Results 1,977 subjects were identified with an index myocardial MI: 2/3
were males, mean age=67.2 y, 20.6% had diabetes, 37.6% hypercholesterol-
emia and 82.4% hypertension. Cumulative incidence rates for outcomes are
shown in the table. All cause mortality at 3 years (including in-hospital death)
was 27% (95% CI: 25.8-29.1). This incidence was high in the 3 months fol-
lowing the index MI stabilized thereafter. 
Conclusion Despite high prescription rates of post-MI treatments, rates of
all-cause mortality and CV events remained high following MI. This under-
scores the need to improve secondary prevention. 
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Background Obstructive Sleep Apnea (OSA) is frequently associated
with cardiovascular disease. Its diagnosis seems to be related with poor
prognosis. 
Aim To determine the prevalence of OSA in patients with acute coronary
syndrome (ACS). Evaluate the prognostic impact of OSA and CPAP therapy
in these patients. 
Methods Prospective study of 73 patients diagnosed with ACS. A poly-
somnography was performed in all patients. An Apnea-hypopnea index >5
was considered diagnostic of OSA and patients were referred to CPAP
therapy. We evaluated the occurrence of the primary composite endpoint of
death, myocardial infarction and revascularization. 
Results The prevalence of OSA was 63.0%. The average age
(62.4±11.3) was similar in both groups. Gender and cardiovascular risk
factors were not significantly different between groups. Patients were
admitted for Non-ST elevation ACS in 60.3% and for ST elevation ACS
Abstratct 0053 – Table
% patients treated
6 months 
before index MI
6 months 
after index MI
Statins 30.7% 91.1%
Ezetimibe 3.6% 4.9%
Aspirine (Alone) 59.9% 11.6%
Aspirine+P2Y12-I* 23.9% 76.0%
Class III Antiarrhytmic 2.4% 8.4%
Oral Anticoagulant 5.1% 10.1%
Non-Thiazide Diuretics 19.1% 32.9%
ACE Inhibitors 18.6% 71.0%
Beta-Blockers 26.5% 86.0%
Nitrates 9.9% 46.4%
Other Antihypertensives** 40.2% 30.3%
Cumulative incidence rate (95%CI)
1 year 2 year 3 year
All cause deaths*** 17.8% 
(16.0%;19.5%)
21.6% 
(20.7%;23.5%)
27.0%
(25.8%;29.1%)
Recurrent MI 3.1% 
(2.3%;3.8%)
4.1% 
(3.2%;5.0%)
4,7% 
(3.7%;5.7%)
Stroke orTIA 1.9% 
(1.3%;2.5%)
3.1% 
(2.3%;3.9%)
4.1% 
(3.1%;5.0%)
Composite of death***/
reinfarction/stroke
20.7% 
(18.9%;22.5%)
26.0% 
(24.0%;28.0%)
32.1%
(29.8%;34.3%)
* mostly clopidogrel
**thiazide diuretics, angiotensin II receptor blockers, CCBs
*** including in-hospital deaths
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in 39.7%. OSA was classified as mild (OSA-M) in 30.4% and as moderate
to severe (OSA-S) in 69.6%. After a median follow-up of 75 months (IQR
71-79), patients with OSA-S showed a significantly higher incidence of
the composite endpoint (relative risk 3.29, 95% CI 1.07-10.10; p=0.038).
Kapplan-Meier survival curves are represented in Figure 1. Adherence to
CPAP was 42.9% and there was a numerically lower proportion of patients
with composite endpoint in the group of compliant patients (33.3% vs.
37.5%, p=NS). 
Conclusions OSA has a high prevalence in ACS patients. Its screening has
high diagnostic yield and allows to identify patients with clearly unfavorable
prognosis and a potentially treatable risk factor. CPAP notes a significant
number of noncompliant, but may improve prognosis, justifying further ran-
domized clinical studies.
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Obesity is an independent risk factor for coronary artery disease and
premature death. However, a number of studies have demonstrated that it
is inversely associated with short-term mortality in patients with acute cor-
onary artery disease. Most data suggesting this “obesity paradox” identify
obesity with body mass index (BMI), but weight was not previously con-
sidered while it could be an alternative measurement that may also prove
to be an accurate predictor of in-hospital mortality. The aim of this study
was to determine whether BMI and weight are related to in-hospital mor-
tality in patients admitted for an acute coronary syndrome (ACS). Data
was derived from the EURHOBOP cohort, a multicenter ACS hospital reg-
istry conducted between 2008 and 2010 in 7 European countries. ACS
patients with discharge diagnosis of myocardial infarction or unstable
angina were included. Socio-demographic characteristics, medical histo-
ries and acute episodes at entry or during hospitalization were recorded.
In-hospital mortality risk by BMI or weight categories were assessed using
multiple logistic regression. A total of 6298 patients were included. Mean
age was 65.3±12.7 years, 75% were men, 27% had diabetes and 63% had
hypertension. ST-elevation ACS was observed in 31% of patients. BMI
ranged from 13.4 to 64.5kg/m2; 46% were overweight (25≤BMI<30) and
24% obese (BMI≥30). Weight ranged from 36 to 190kg. Mortality rate
was 3.1% [95% CI:2.7%-3.5%]. Based on ROC curves, optimal cutoff
points to predict in-hospital survival were 26kg/m2 for BMI and 75kg for
weight. In univariate logistic regression, BMI≥26kg/m2 (OR=0.69; [95%
CI]:0.52-0.92) or weight≥75kg (OR=0.57;[95% CI]:0.43-0.76) had a sig-
nificant protective association with mortality. However, none of these
associations remained significant in multivariate analysis. In EURHOBOP,
higher BMI and weight in ACS patients were not associated with better
short term in-hospital mortality.
The author hereby declares no conflict of interest
0019
High-degree atrioventricular block complicating ST-segment eleva-
tion myocardial infarction in the contemporary era: data from the
ORBI prospective French regional registry 
Vincent Auffret* (1), Aurélie Loirat (2), Guillaume Leurent (2),
Raphael Martins (2), Emmanuelle Filippi (3), Isabelle Coudert (4),
Jean-Philippe Hacot (5), Martine Gilard (6), Philippe Castellant (6),
Antoine Rialan (7), Régis Delaunay (7), Gilles Rouault (8), Philippe
Druelles (9), Bertrand Boulanger (9), Josiane Treuil (9), Bertrand Avez
(2), Marc Bedossa (2), Dominique Boulmier (2), Marielle le Guellec
(2), Jean-Claude Daubert(2), Hervé le Breton (2)
(1) CHU Rennes, Rennes, France – (2) CHU Rennes, Pontchaillou, Rennes,
France – (3) CH Vannes, Vannes, France – (4) CH St-Brieuc, Saint Brieuc,
France – (5) CH Lorient, Lorient, France – (6) CHU Brest, La Cavale
Blanche, Brest, France – (7) CH St-Malo, Saint-Malo, France –
(8) CH Quimper, Quimper, France – (9) Polyclinique Saint-Laurent, Rennes,
France
*Corresponding author: v.auffret@gmail.com (Vincent Auffret)
Background High-degree atrioventricular block (HAVB) is a common
complication of ST-segment elevation myocardial infarction (STEMI). HAVB
in STEMI is historically considered as a marker of worse outcome but overall
data about HAVB in the contemporary era of mechanical reperfusion and
potent antiplatelet therapies are scarce.
Aim We aimed at analyzing incidence, clinical correlates and impact on in-
hospital outcomes of HAVB in a large prospective registry (ORBI) of modern
management of STEMI with a special focus on potential differences between
patients with HAVB on admission and those who developed HAVB during
hospitalization.
Methods All patients enrolled in ORBI between June 2006 and December
2013 were included in the present analysis and were divided into 3 groups:
patients without HAVB at any time, patients with HAVB on admission and
those who developed HAVB during hospitalization. 
Results 6662 patients (age: 62.0 [52.0-74.0]; male: 76.3%) were
included in the present analysis. HAVB was documented in 3.5% of
patients, present on admission in 63.7% of patients and occurring during
hospitalization in 36.3%. Patients with HAVB on admission or occurring
during the first 24h of hospitalization had higher in-hospital mortality rates
(18.1% and 28.6% respectively) than patients without (4.5%) or with
HAVB occurring beyond the first 24h of hospitalization (8.0%). However
by multivariable analysis, HAVB was not independently associated with
in-hospital mortality. 
Conclusion Patients with HAVB had a higher mortality rate than patients
without. However HAVB is not an independent predictor of in-hospital mortality. 
The author hereby declares no conflict of interest
OSA severity
Non-OSA
Mild-OSA
Moderate-to-severe-
OSA
Non-OSA-censored
Mild-OSA-censored
Moderate-to-severe-
OSA-censored
Log Rank = 0.038
Time (months)
D
ea
th
, M
I a
nd
 R
ev
a
sc
u
la
ri
za
tio
n 
Su
rv
iv
a
l
0 20 40 60 80 100
1,0
0,8
0,6
0,4
0,2
0,0
Abstract 0363 – Figure
